Latest News
|
24 April 2013
0 Likes 
The US' Patient-Centered Outcomes Research Institute (PCORI), a budding comparative effectiveness research (CER) organization formed under the Patient Protection and Affordable Care Act (PPACA) of
Read More...
Latest News
Regulatory Update
|
10 April 2013
0 Likes
The UK cost containment agency, the National Institute for Health and Care Excellence (NICE), recommended on 9 April 2013 reimbursement for two in vitro diagnostic (IVD) devices for detecting
Read More...
Regulatory Update
|
28 March 2013
0 Likes
The UK’s cost containment agency, the National Institute for Health and Clinical Excellence (NICE), has recommended reimbursement for tobramycin (Tobi Podhaler, Novartis) and colistimethate sodium
Read More...
Latest News
Regulatory Update
|
27 March 2013
0 Likes
The US Patient-Centered Outcomes Research Institute's (PCORI) Board of Governors announced on 26 March 2013 that it had selected 84 people to serve on its first four advisory panels, staffing the
Read More...
Latest News
Regulatory Update
|
21 March 2013
0 Likes
The UK’s cost containment agency, the National Institute of Health and Clinical Excellence (NICE), has issued its final appraisal determination recommending reimbursement by the National Health
Read More...
Latest News
Regulatory Update
|
21 February 2013
0 Likes
The UK’s cost containment agency, the National Institute of Health and Clinical Excellence (NICE), has agreed to recommend the use of an innovative new diagnostic test designed to guide the use of
Read More...
Latest News
|
11 February 2013
0 Likes
Even casual observers of US healthcare policy are aware of a common refrain: Costs are too high, unsustainable and a poor indicator for the quality US patients ought to be receiving. While the reasons
Read More...
Latest News
Regulatory Update
|
1 February 2013
0 Likes
In draft guidance published on 31 January 2013, the UK's health technologies assessment body, the National Institute of Health and Clinical Excellence (NICE), does not recommend the use of
Read More...
Latest News
Regulatory Update
|
16 January 2013
0 Likes
France’s cost containment agency (HAS) is undertaking a health technology assessment review of all implantable spinal neurostimulation devices, whether rechargeable or not, that are intended for the
Read More...
Latest News
Regulatory Update
|
18 December 2012
0 Likes
The UK’s cost containment agency, the National Institute for health and Clinical Excellence (NICE), has issued draft guidance saying that while Roche’s blockbuster cancer drug Avastin (bevacizumab)
Read More...